Peng Lv1, 2, Baiji Xue2, *, Yongsheng Wang1, *
1School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China - 2School of Basic Medical Sciences, Baicheng Medical College, Baicheng 137000, China
Objective: Glioma is one of the most common invasive tumors in the central nervous system, which can not significantly prolong the survival time of patients after treatment. As a new tumor therapy, immunotherapy can specifically treat gliomas, but its clinical application is still less. To investigate the immunological characteristics and immunoteerapy of gliomas reported so far, and to summarize the application experience.
Methods: By consulting the relevant literature on the treatment of glioma at home and abroad, I briefly describe the immunological characteristics of glioma and the existing immunotherapy methods of brain therapy.
Results: We found that the incidence of glioma was high, and the effects of existing surgery, radiotherapy and temozolomide therapy were not good. The researchers found that the immune escape pathway of glioma can be intervened through the immune response deficiency of glioma cells, and the effective immunotherapy for glioma can be carried out. This gives rise to new therapies, immunotherapies.
Conclusion: Through the unremitting efforts of medical researchers, active immunotherapy, passive immunotherapy and other immunotherapy have achieved good results in inhibiting tumor proliferation and promoting tumor cell apoptosis.
Glioma, blood-brain barrier, immunotherapy, vaccine.
10.19193/0393-6384_2021_1_96